Literature DB >> 25217553

Fatal intoxications associated with the designer opioid AH-7921.

R Kronstrand1, G Thelander2, D Lindstedt2, M Roman2, F C Kugelberg3.   

Abstract

AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) is a designer opioid with ∼80% of morphine's µ-agonist activity. Over a 6-month period, we encountered nine deaths where AH-7921 was involved and detected in blood from the deceased. Shortly after the last death, on August 1 2013, AH-7921 was scheduled as a narcotic and largely disappeared from the illicit market in Sweden. AH-7921 was measured by a selective liquid chromatography-MS-MS method and the concentrations of AH-7921 ranged from 0.03 to 0.99 µg/g blood. Six of our cases had other drugs of abuse on board and most had other medications such as benzodiazepines, antidepressants and analgesics. However, the other medicinal drugs encountered were present in postmortem therapeutic concentrations and unlikely to have contributed to death. In addition to the parent compound, we identified six possible metabolites where two N-demethylated dominated and four mono-hydroxylated were found in trace amounts in the blood. In conclusion, deaths with AH-7921 seem to occur both at low and high concentrations, probably a result of different tolerance to the drug. Hence, it is reasonable to assume that no sharp dividing line exists between lethal and non-lethal concentrations. Further, poly-drug use did not seem to be a major contributing factor for the fatal outcome.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217553     DOI: 10.1093/jat/bku057

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  13 in total

1.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Shaokun Pang; Mingshe Zhu; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-09-01       Impact factor: 3.345

Review 2.  AH-7921: A review of previously published reports.

Authors:  Kerry Anne Rambaran; Zubair M Amin; Steven W Fleming; Liza Chacko; Saeed K Alzghari
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-06-01

Review 3.  Blood concentrations of new synthetic opioids.

Authors:  Piotr Adamowicz; Karolina Nowak
Journal:  Int J Legal Med       Date:  2021-10-22       Impact factor: 2.686

Review 4.  Misuse of Novel Synthetic Opioids: A Deadly New Trend.

Authors:  Matthew P Prekupec; Peter A Mansky; Michael H Baumann
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

Review 5.  An Expanding World of Novel Psychoactive Substances: Opioids.

Authors:  Jolanta B Zawilska
Journal:  Front Psychiatry       Date:  2017-06-30       Impact factor: 4.157

6.  Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids.

Authors:  Renata Solimini; Simona Pichini; Roberta Pacifici; Francesco P Busardò; Raffaele Giorgetti
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

Review 7.  Postmortem Toxicology of New Synthetic Opioids.

Authors:  Marta Concheiro; Rachel Chesser; Justine Pardi; Gail Cooper
Journal:  Front Pharmacol       Date:  2018-10-26       Impact factor: 5.810

8.  Antinociceptive and Discriminative Stimulus Effects of Six Novel Psychoactive Opioid Substances in Male Rats.

Authors:  Ellen A Walker; Christina Chambers; Matthew G Korber; Srihari R Tella; Cassandra Prioleau; Li Fang
Journal:  J Pharmacol Exp Ther       Date:  2021-07-08       Impact factor: 4.402

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

Review 10.  Novel Synthetic Opioids: The Pathologist's Point of View.

Authors:  Paolo Frisoni; Erica Bacchio; Sabrine Bilel; Anna Talarico; Rosa Maria Gaudio; Mario Barbieri; Margherita Neri; Matteo Marti
Journal:  Brain Sci       Date:  2018-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.